Epilepsy Therapeutics Market Strategy Analysis And Trends To 2019
In 2012, the overall industry for epilepsy therapeutics in the major developed markets contributed for an approximate share of over $3.1 billion. Furthermore, this market is anticipated to expand at a total CAGR of over 3.3% to cross over $4.2 billion over the forecast period till 2019.
In 2012, the overall industry for epilepsy therapeutics in the major developed markets contributed for an approximate share of over $3.1 billion. Furthermore, this market is anticipated to expand at a total CAGR of over 3.3% to cross over $4.2 billion over the forecast period till 2019.
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
4.3.3 Clinical Trial Duration 36<br />
4.4 Promising Pipeline Candidates 38<br />
4.4.1 Brivaracetam - UCB 38<br />
4.4.2 Ganaxolone - Marinus Pharmaceuticals 38<br />
5 <strong>Epilepsy</strong> <strong>Therapeutics</strong> <strong>Market</strong> Forecast to <strong>2019</strong> 39<br />
5.1 Geographical <strong>Market</strong>s 39<br />
5.1.1 Major Developed <strong>Market</strong>s 39<br />
5.1.2 The US 40<br />
5.1.3 <strong>To</strong>p Five EU Countries 43<br />
5.1.4 Japan 46<br />
5.1.5 Canada 48<br />
5.2 Drivers and Barriers 50<br />
5.2.1 Drivers 50<br />
5.2.2 Barriers 50<br />
6 Deals and Strategic Consolidations 52<br />
6.1 Deals <strong>Analysis</strong> 52<br />
6.2 Research and Development Co-development Agreements 54<br />
6.3 Research and Development Licensing Agreements 55<br />
<strong>To</strong> Get Sample Copy of Report visit @ http://www.radiantinsights.com/research/epilepsytherapeutics-in-major-developed-markets-to-<strong>2019</strong>-new-aeds-with-novel-mechanisms-ofaction-signal-a-shift-in-treatment-patterns#tabs-4<br />
7 Appendix 57<br />
7.1 Abbreviations 57<br />
7.2 References 58<br />
7.3 References for Heat Maps 62<br />
7.4 Pipeline Products by Phase 63<br />
7.4.1 Discovery 63<br />
7.4.2 Preclinical 63<br />
7.4.3 IND-filed and Phase 0 64<br />
7.4.4 Phase I 65<br />
7.4.5 Phase II 65<br />
7.4.6 Phase III 66<br />
7.4.7 Pre-registration 66<br />
7.5 <strong>Market</strong> Forecasting Data Tables to <strong>2019</strong> 67<br />
7.5.1 Major Developed <strong>Market</strong>s 67<br />
7.5.2 US 67<br />
7.5.3 UK 67<br />
7.5.4 France 68<br />
7.5.5 Germany 68<br />
7.5.6 Italy 68<br />
7.5.7 Spain 69
Change language